Abstract YO37
Case summary
57-year-old man presented with chronic progressive headache for 3 months. He initially visited hospital due to chronic headache with projectile vomiting and ataxia. He also had anorexia and lost 7 kg but he had no respiratory tract symptoms including chronic cough, dyspnea, and chest pain. His smoking history was about 10 pack-year. On his physical examination, pupils with 4 mm. in size and reactive to light, papilledema both eyes and tongue deviation to the left side were detected but others were unremarkable. His routine investigations including chest radiography were unremarkable. He was evaluated with MRI of the brain which showed multiple enhancing lesions at the left lateral ventricle, left temporal horn, 4th ventricle, bilateral foramen of Luschka and both sides of foramen magnum with obstructive hydrocephalus. Consequently, he was diagnosed of intraventricular papilloma and underwent craniotomy with tumor removal and ventriculoperitoneal shunt. Subsequently, he received whole brain radiation therapy for 200 cGy. The pathological result from his intraventricular mass demonstrated papillary tumor with hobnail appearance and further immunohistochemistry was processed. The final result showed strongly diffuse positive AE1/AE3, EMA, CK7, TTF-1, and NapsinA while negative CK20 and Thyroglobulin. Consequently, it was compatible with metastatic adenocarcinoma, most likely from primary lung carcinoma. Further molecular testing demonstrated EGFR Exon 19 deletion mutation by PCR but no detection of ALK rearrangement. Later, he was evaluated with CT of the chest and upper abdomen which showed a 2.4x1.3 cm spiculated pulmonary mass at the apicoposterior segment of the left upper lobe and 0.8 cm pathological lymph node at AP window region. Bone metastasis at T3 vertebral bodies was also seen. Finally, he was diagnosed as adenocarcinoma of the left lung with intraventricular metastasis; stage T1cN2M1b. After completion of WBRT, his neurologic symptoms were improved and he still had no respiratory tract symptoms. His ECOG performance status was 1. Discussing treatment options, the patient and his family made a decision to enroll in the clinical trial for new EGFR TKI.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract